drugset / Trial / NCT02002325

THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)

NCT02002325 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to clarify efficacy and safety of MRI-based intravenous thrombolysis with alteplase for patients with acute wake-up ischemic stroke and those having acute ischemic stroke with unknown time of symptom onset.

Timeline

Start
2014-05
Primary completion
2019-12
Completion
2020-03

Outcome

Missed primary endpoint

paper Favorable outcome was comparable between the alteplase group (32/68, 47.1%) and the control group (28/58, 48.3%; relative risk [RR], 0.97 [95% CI, 0.68-1.41]; P=0.892). PMID 32248771 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.6 mg/kg Intravenous

Indications